Annual report pursuant to Section 13 and 15(d)

Organization and Principal Activities - Additional Information (Details)

v3.23.1
Organization and Principal Activities - Additional Information (Details)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
USD ($)
Segment
shares
Dec. 31, 2020
USD ($)
shares
Dec. 31, 2021
USD ($)
Organization Consolidation And Presentation Of Financial Statements [Line Items]      
Date of incorporation Apr. 21, 2003    
Number of operating segments | Segment 1    
Accumulated deficit $ 452,615   $ 333,411
Net proceeds from issuance of common stock 56,270 $ 251,415  
Unrestricted cash, cash equivalents and marketable securities $ 302,300    
Substantial doubt about going concern, within one year false    
Headquartered in South San Francisco    
Headquartered in state CA    
Vaxcyte      
Organization Consolidation And Presentation Of Financial Statements [Line Items]      
Unrestricted cash cash equivalents and equity securities at carrying value $ 32,000    
Minimum      
Organization Consolidation And Presentation Of Financial Statements [Line Items]      
Period from issuance date of unaudited interim condensed financial statements 12 months    
Common Stock      
Organization Consolidation And Presentation Of Financial Statements [Line Items]      
Shares of common stock | shares   19,550,000  
Common Stock | At-the-Market (“ATM")      
Organization Consolidation And Presentation Of Financial Statements [Line Items]      
Shares of common stock | shares 10,285,160    
Gross proceeds from issuance of common stock $ 58,300    
Underwriting discounts and commissions and other offering expenses 2,000    
Net proceeds from issuance of common stock $ 56,300